Renascience Inc. (TYO:4889)
Japan · Delayed Price · Currency is JPY 1,529.00
+203.00 (15.31%)
Jun 3, 2026, 3:30 PM JST
Renascience Revenue
In the fiscal year ending March 31, 2026, Renascience had annual revenue of 68.00M JPY, down -48.48%. Renascience had revenue of 28.00M in the quarter ending March 31, 2026, a decrease of -58.21%.
Revenue
68.00M
Revenue Growth
-48.48%
P/S Ratio
268.65
Revenue / Employee
n/a
Employees
3
Market Cap
18.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 68.00M | -64.00M | -48.48% |
| Mar 31, 2025 | 132.00M | -62.00M | -31.96% |
| Mar 31, 2024 | 194.00M | 94.00M | 94.00% |
| Mar 31, 2023 | 100.00M | -39.00M | -28.06% |
| Mar 31, 2022 | 139.00M | -70.00M | -33.49% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.81B |
| ReproCELL | 2.23B |
| Japan Tissue Engineering | 2.18B |
| Immuno-Biological Laboratories | 1.00B |
| AnGes | 908.00M |
| Stella Pharma | 323.00M |
| Cuorips | 212.00M |
| Nano Holdings | 174.00M |